Korro Bio to Cut 20% of Workforce

Dow Jones

May 08

By Kelly Cloonan

Korro Bio plans to cut about 20% of its workforce in an attempt to streamline operations and reach key program milestones.

The clinical-stage biopharmaceutical company said Wednesday the restructuring will incur one-time charges of around $1.2 million, including employee severance, benefits and other termination costs. It expects to recognize the majority of those charges in the second quarter.

Korro had 104 full-time employees as of Dec. 31, according to the company's most recent 10K filing.

The actions will help the company complete its Phase 1/2a Rewrite clinical trial in 2026, nominate a second development candidate and advance up to two programs under a collaboration with Novo Nordisk, Korro said.

The company will also continue to prioritize the development of KRRO-110 alongside investments in its Oligonucleotide Promoted Editing of RNA platform.

Based in Cambridge, Mass., Korro is focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 07, 2025 18:29 ET (22:29 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533958439"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533958439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533958439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 06:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533958439","market":"other","top_or_hot":-1,"title":"Korro Bio to Cut 20% of Workforce","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Korro Bio plans to cut about 20% of its workforce in an attempt to streamline operations and reach key program milestones. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Wednesday the restructuring will incur one-time charges of around $1.2 million, including employee severance, benefits and other termination costs. It expects to recognize the majority of those charges in the second quarter. \n</p>\n<p>\n  Korro had 104 full-time employees as of Dec. 31, according to the company's most recent 10K filing. \n</p>\n<p>\n  The actions will help the company complete its Phase 1/2a Rewrite clinical trial in 2026, nominate a second development candidate and advance up to two programs under a collaboration with Novo Nordisk, Korro said. \n</p>\n<p>\n  The company will also continue to prioritize the development of KRRO-110 alongside investments in its Oligonucleotide Promoted Editing of RNA platform. \n</p>\n<p>\n  Based in Cambridge, Mass., Korro is focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 18:29 ET (22:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio to Cut 20% of Workforce</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio to Cut 20% of Workforce\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-08 06:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Korro Bio plans to cut about 20% of its workforce in an attempt to streamline operations and reach key program milestones. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Wednesday the restructuring will incur one-time charges of around $1.2 million, including employee severance, benefits and other termination costs. It expects to recognize the majority of those charges in the second quarter. \n</p>\n<p>\n  Korro had 104 full-time employees as of Dec. 31, according to the company's most recent 10K filing. \n</p>\n<p>\n  The actions will help the company complete its Phase 1/2a Rewrite clinical trial in 2026, nominate a second development candidate and advance up to two programs under a collaboration with Novo Nordisk, Korro said. \n</p>\n<p>\n  The company will also continue to prioritize the development of KRRO-110 alongside investments in its Oligonucleotide Promoted Editing of RNA platform. \n</p>\n<p>\n  Based in Cambridge, Mass., Korro is focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 18:29 ET (22:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533958439","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533958439","pubTimestamp":1746656940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Korro Bio plans to cut about 20% of its workforce in an attempt to streamline operations and reach key program milestones.The clinical-stage biopharmaceutical company said Wednesday the restructuring will incur one-time charges of around $1.2 million, including employee severance, benefits and other termination costs. It expects to recognize the majority of those charges in the second quarter.Korro had 104 full-time employees as of Dec. 31, according to the company's most recent 10K filing.The actions will help the company complete its Phase 1/2a Rewrite clinical trial in 2026, nominate a second development candidate and advance up to two programs under a collaboration with Novo Nordisk, Korro said.The company will also continue to prioritize the development of KRRO-110 alongside investments in its Oligonucleotide Promoted Editing of RNA platform.Based in Cambridge, Mass., Korro is focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KRRO":"Korro Bio, Inc."},"translate_title":"Korro Bio将裁员20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Korro Bio plans to cut about 20% of its workforce in an attempt to streamline operations and reach key program milestones. \n\n\n  The clinical-stage biopharmaceutical company said Wednesday the restructuring will incur one-time charges of around $1.2 million, including employee severance, benefits and other termination costs. It expects to recognize the majority of those charges in the second quarter. \n\n\n  Korro had 104 full-time employees as of Dec. 31, according to the company's most recent 10K filing. \n\n\n  The actions will help the company complete its Phase 1/2a Rewrite clinical trial in 2026, nominate a second development candidate and advance up to two programs under a collaboration with Novo Nordisk, Korro said. \n\n\n  The company will also continue to prioritize the development of KRRO-110 alongside investments in its Oligonucleotide Promoted Editing of RNA platform. \n\n\n  Based in Cambridge, Mass., Korro is focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2025 18:29 ET (22:29 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}